TY - JOUR T1 - A pilot study comparing low-dose liposomal amphotericin B with N-methyl glucamine for the treatment of American cutaneous leishmaniasis. AU - Motta,J O C, AU - Sampaio,R N R, Y1 - 2011/04/15/ PY - 2011/4/16/entrez PY - 2011/4/16/pubmed PY - 2012/6/26/medline SP - 331 EP - 5 JF - Journal of the European Academy of Dermatology and Venereology : JEADV JO - J Eur Acad Dermatol Venereol VL - 26 IS - 3 N2 - BACKGROUND: Cutaneous leishmaniasis is an infectious re-emerging disease that has increased in incidence worldwide. Antimony, a highly toxic drug, remains the first choice therapy to treat it. Liposomal amphotericin B is active against Leishmania and is less toxic than antimony. OBJECTIVE: To compare low-dose liposomal amphotericin B with N-methyl glucamine for the treatment of American cutaneous leishmaniasis. PATIENTS/METHODS: In a controlled open-label trial 35 patients with a localized form of American cutaneous leishmaniasis were included. They were allocated to a first group treated with 1.5 mg/kg/day of liposomal amphotericin B for 5 days, or to a second one treated with 20 mgSbV/kg/day of N-methyl glucamine for 20 days. RESULTS: In the first group, 50% and 81% of patients experienced a clinical cure and clinical improvement respectively. There was a 100% clinical cure in the second group. CONCLUSION: Liposomal amphotericin B seems to be promising and safe for the treatment of American cutaneous leishmaniasis. SN - 1468-3083 UR - https://www.unboundmedicine.com/medline/citation/21492255/A_pilot_study_comparing_low_dose_liposomal_amphotericin_B_with_N_methyl_glucamine_for_the_treatment_of_American_cutaneous_leishmaniasis_ L2 - https://doi.org/10.1111/j.1468-3083.2011.04070.x DB - PRIME DP - Unbound Medicine ER -